Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
ZacksThe U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.